Multiple sclerosis imaging: Recent advances

Journal of Neurology

Volumn 260, Issue 3, 2013, Pages 929-935

  Rocca, Maria A ^a   Messina, Roberta ^a   Filippi, Massimo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Diagnosis; Disability; Magnetic resonance imaging; Multiple sclerosis; Treatment

Indexed keywords

BUTYLCRESOL; GADOLINIUM; GLATIRAMER; NATALIZUMAB;

ARTICLE; CEREBELLUM; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; CORPUS CALLOSUM; DIFFERENTIAL DIAGNOSIS; DISABILITY; EARLY DIAGNOSIS; EXPANDED DISABILITY STATUS SCALE; FATIGUE; GRAY MATTER; HUMAN; JUXTACORTICAL WHITE MATTER; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATHOPHYSIOLOGY; PERIVENTRICULAR WHITE MATTER; PONS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; WHITE MATTER;

ANIMALS; COGNITION DISORDERS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; QUALITY OF LIFE;

EID: 84876474662     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6788-8     Document Type: Article

References (55)

1. The Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727-732
2. Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, Stromillo ML, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N (2007) Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64:1157-1161
3. Barkhof F, Filippi M, Miller DH, Tofts P, Kappos L, Thompson AJ (1997) Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 244:76-84
4. Batista S, Zivadinov R, Hoogs M, Bergsland N, Heininen-Brown M, Dwyer MG, Weinstock-Guttman B, Benedict RH (2012) Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 259:139-146
5. Bot JC, Barkhof F (2009) Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. Neuroimaging Clin N Am 19:81-99
6. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66:1144-1150
7. Charil A, Yousry TA, Rovaris M, Barkhof F, De Stefano N, Fazekas F, Miller DH, Montalban X, Simon JH, Polman C, Filippi M (2006) MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol 5:841-852
8. Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139-1151
9. Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, Yang M, Hulme A, O'Connor P, Miller DH (2004) Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 251:407-413
10. Eckstein C, Saidha S, Levy M (2012) A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol 259:801-816
11. Filippi M, Agosta F, Spinelli EG, Rocca MA (2012) Imaging resting state brain function in multiple sclerosis. J Neurol. doi: 10.1007/s00415-012-6695-z
12. Filippi M, Horsfield MA, Ader HJ, Barkhof F, Bruzzi P, Evans A, Frank JA, Grossman RI, McFarland HF, Molyneux P, Paty DW, Simon J, Tofts PS, Wolinsky JS, Miller DH (1998) Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 43:499-506
13. Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V (2011) Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 76:1222-1228
14. Filippi M, Rocca MA, Colombo B, Falini A, Codella M, Scotti G, Comi G (2002) Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 15:559-567
15. Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G (2011) Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 68:1514-1520
16. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57:731-733
17. Goodin DS (2006) Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 59:597-605
18. Hackmack K, Weygandt M, Wuerfel J, Pfueller CF, Bellmann-Strobl J, Paul F, Haynes JD (2012) Can we overcome the 'clinico-radiological paradox' in multiple sclerosis? J Neurol 259:2151-2160
19. Harrison DM, Shiee N, Bazin PL, Newsome SD, Ratchford JN, Pham D, Calabresi PA, Reich DS (2012) Tract-specific quantitative MRI better correlates with disability than conventional MRI in multiple sclerosis. J Neurol. doi: 10.1007/s00415-012-6638-8
20. Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kumpfel T (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258:1665-1669
21. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254-260
22. Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hunter K, Tozer DJ, Miller DH, Kapoor R (2012) Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol 259:237-245
23. Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hunter K, Tozer DJ, Miller DH, Kapoor R (2012) Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine. J Neurol 259:505-514
24. Hellwig K, Gold R (2011) Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 258:1920-1928
25. Hickman SJ, Dalton CM, Miller DH, Plant GT (2002) Management of acute optic neuritis. Lancet 360:1953-1962
26. Horwitz H, Degn M, Modvig S, Larsson HB, Wanscher B, Frederiksen JL (2012) CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis. J Neurol 259:2616-2620
27. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9:681-688
28. Kleinfeld K, Mobley B, Hedera P, Wegner A, Sriram S, Pawate S (2012) Adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia: report of five cases and a new mutation. J Neurol. doi: 10.1007/s00415-012-6680- 6
29. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
30. Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081-1087
31. Melin A, Outteryck O, Collongues N, Zephir H, Fleury MC, Blanc F, Lacour A, Ongagna JC, Berteloot AS, Vermersch P, de Seze J (2012) Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol 259:1215-1221
32. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14:1157-1174
33. Nociti V, Batocchi AP, Luigetti M, Conte A, Lorusso VS, Roiati S, Tartaglione T, Del Grande A, Sabatelli M (2011) Progressive ascending myelopathy: atypical forms of multiple sclerosis or what else? J Neurol 258:1965-1970
34. Ormerod IE, Miller DH, McDonald WI, du Boulay EP, Rudge P, Kendall BE, Moseley IF, Johnson G, Tofts PS, Halliday AM et al (1987) The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quant study. Brain 110(Pt 6):1579-1616
35. Paling D, Golay X, Wheeler-Kingshott C, Kapoor R, Miller D (2011) Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol 258:2113-2127
36. Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman L, Cutter G, Kappos L, Radue EW (2012) Evolution of MS lesions to black holes under DNA vaccine treatment. J Neurol 259:1375-1382
37. Pardini M, Bonzano L, Mancardi GL, Roccatagliata L (2010) Frontal networks play a role in fatigue perception in multiple sclerosis. Behav Neurosci 124:329-336
38. Patrucco L, Rojas JI, Cristiano E (2012) Assessing the value of spinal cord lesions in predicting development of multiple sclerosis in patients with clinically isolated syndromes. J Neurol 259:1317-1320
39. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
40. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 69:292-302
41. Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685-691
42. Reilmann R, Holtbernd F, Bachmann R, Mohammadi S, Ringelstein EB, Deppe M (2012) Grasping multiple sclerosis: do quantitative motor assessments provide a link between structure and function? J Neurol. doi: 10.1007/s00415-012-6639-7
43. Riccitelli G, Rocca MA, Forn C, Colombo B, Comi G, Filippi M (2011) Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. AJNR Am J Neuroradiol 32:874-879
44. Rieckmann P, Boyko A, Centonze D, Coles A, Elovaara I, Havrdova E, Hommes O, Lelorier J, Morrow SA, Oreja-Guevara C, Rijke N, Schippling S (2012) Future MS care: a consensus statement of the MS in the 21st Century Steering Group. J Neurol. doi: 10.1007/s00415-012-6656-6
45. Rocca MA, Absinta M, Filippi M (2012) The role of advanced magnetic resonance imaging techniques in primary progressive MS. J Neurol 259:611-621
46. Rocca MA, Agosta F, Colombo B, Mezzapesa DM, Falini A, Comi G, Filippi M (2007) fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection. Hum Brain Mapp 28:373-382
47. Sepulcre J, Masdeu JC, Goni J, Arrondo G, Velez de Mendizabal N, Bejarano B, Villoslada P (2009) Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler 15:337-344
48. Sicotte NL, Kern KC, Giesser BS, Arshanapalli A, Schultz A, Montag M, Wang H, Bookheimer SY (2008) Regional hippocampal atrophy in multiple sclerosis. Brain 131:1134-1141
49. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 65:268-275
50. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P (2010) Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-anal approach. Neurol 75:302-309
51. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743-747
52. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70:1150-1151
53. Yaldizli O, Glassl S, Sturm D, Papadopoulou A, Gass A, Tettenborn B, Putzki N (2011) Fatigue and progression of corpus callosum atrophy in multiple sclerosis. J Neurol 258:2199-2205
54. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924-933
55. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M (2012) MRI pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. doi: 10.1002/ana.23676